Core Viewpoint - BrainsWay Ltd. has made two additional strategic minority stake investments in U.S. mental health providers, bringing the total to four in 2025, aiming to enhance patient access to innovative mental health treatments and drive long-term shareholder value [1][2][5] Investment Details - BrainsWay will invest an initial $1.5 million in Heading Health, with the potential for an additional $2.5 million through three milestone-based investments [3] - The investment in Heading Health will provide BrainsWay with a minority position in the form of a preferred, annually compounding security [3] Strategic Intent - The investment strategy is designed to facilitate the growth of commercial partners while allowing BrainsWay to maintain its focus on scientific and technological advancements [4] - The partnership with Heading Health is seen as a unique opportunity to expand treatment options and improve patient lives on a large scale [5] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [6] - The company has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [6] Heading Health Overview - Heading Health specializes in interventional psychiatry, focusing on effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression [7] - The organization employs a team of board-certified psychiatrists and advanced psychiatric nurse practitioners to deliver cutting-edge treatment options [7]

Core Viewpoint - BrainsWay is strategically investing in minority positions in leading U.S. mental health providers to enhance awareness and access to innovative mental health treatments, particularly Deep TMS Therapy [1][2]. Investment Details - BrainsWay has entered into a strategic equity financing agreement with Axis Management Company, Inc., committing an initial investment of $2.3 million, with a potential additional $1 million based on milestones [1]. - The investment will be in the form of a preferred, annually compounding security, and includes a redemption mechanism for the shares [1]. Strategic Goals - The investment in Axis is part of BrainsWay's broader initiative to accelerate access to innovative mental health treatments while maintaining a focus on advancing scientific and technological capabilities [2]. - The company aims to provide capital injections into high-performing healthcare providers, enabling them to invest in growth and expand their services [2]. Axis Management Company Overview - Axis Integrated Mental Health is a management services organization that operates several mental health clinics in Colorado, focusing on delivering comprehensive and integrative care [4]. - The organization combines modern psychiatry and psychotherapy with advanced treatments, including Deep TMS and Spravato, to provide a holistic therapeutic approach [4]. BrainsWay Overview - BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, particularly known for its proprietary Deep TMS technology [3]. - The company has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and is committed to increasing global awareness and access to Deep TMS [3].

Core Insights - BrainsWay has entered into a strategic equity financing agreement with Stella MSO, LLC to enhance access to mental health care and raise awareness of innovative treatments [1][2] - The investment in Stella is part of a broader strategy to make minority-stake investments in high-performing mental health providers across the U.S. [2] - BrainsWay will invest $5 million in Stella, acquiring a minority position in the company through preferred, annually compounding securities [4] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [5] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay aims to increase global awareness and access to Deep TMS through ongoing clinical trials and scientific advancements [5] Stella Overview - Stella is an interventional psychiatry practice focused on effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression [6] - The organization has a strong reputation for clinical excellence and operational strength, having treated over 30,000 patients across more than 20 clinics [1][6] - Stella's partnership with BrainsWay is expected to accelerate its growth and enhance patient care [3][5]

Core Insights - BrainsWay Ltd. has entered into a strategic equity financing agreement with Stella MSO, LLC to enhance access to innovative mental health treatments [1][2] - The investment of $5 million will provide BrainsWay with a minority position in Stella, aimed at supporting the interventional psychiatry space [4][2] - This partnership is expected to accelerate growth and improve patient care through Stella's established network of mental health clinics [3][5] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep TMS™ technology [5] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay is focused on advancing neuroscience and increasing global awareness of its treatment options [5] Stella Overview - Stella is an interventional psychiatry practice that addresses severe trauma, stress, anxiety, and depression through a multidisciplinary approach [6] - The organization has a strong reputation for clinical excellence and operational strength, having treated over 30,000 patients [1][6] - Stella aims to expand access to transformative mental health care through its network of clinics [3][5]

Core Insights - BrainsWay Ltd. achieved record quarterly sales of $11.5 million in Q1 2025, marking a 27% increase compared to Q1 2024 [1][8] - The company reported an operating profit of $0.6 million, a significant increase of 519% year-over-year, and Adjusted EBITDA rose to $1.3 million, up 81% from the previous year [1][8] - The demand for Deep TMS Systems is strong, with a record shipment of 81 systems in Q1 2025, representing a 42% increase from 57 systems shipped in the same period last year [1][8] Financial Performance - Revenue for Q1 2025 was $11.5 million, up 27% from $9.1 million in Q1 2024 [8][21] - Gross margin remained stable at 75% compared to the prior year [8] - Net profit surged by 897% to $1.1 million in Q1 2025, compared to $0.1 million in Q1 2024 [1][8] Operational Highlights - The company is reiterating its full-year 2025 financial guidance, projecting revenue between $49 million to $51 million, with an operating profit margin of 3% to 4% and Adjusted EBITDA of 11% to 12% [5][8] - BrainsWay's CEO highlighted the growing demand for their technology in treating various mental health disorders, including OCD and anxious depression, and emphasized the importance of relationships with large enterprise customers [5][6] Market Expansion - The company is expanding its global market presence, now operating in key markets including Canada, Asia, India, and Europe [6] - Upcoming catalysts for growth include the next-generation Deep TMS 360™ system and the expansion into new indications supported by additional clinical data [6]

Company Overview - BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, specifically through its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology [4] - The company has obtained three FDA-cleared indications for Deep TMS, which include Major Depressive Disorder (MDD), Anxious Depression, Obsessive-Compulsive Disorder (OCD), and Smoking Addiction [4] - Founded in 2003, BrainsWay operates in both Israel and the U.S. and is committed to increasing global awareness and access to Deep TMS [4] Industry Participation - BrainsWay will participate in the American Psychiatric Association (APA) Annual Meeting from May 17–21, 2025, in Los Angeles, California, showcasing its role in psychiatric care [1] - The company will host live demonstrations of its Deep TMS system at its exhibit booth, providing hands-on interaction with this innovative treatment modality [3] Educational Initiatives - A master course titled "Clinical Applications for Psychiatric Practice: Ketamine and TMS" will be held on May 18, 2025, focusing on integrating novel treatments into clinical psychiatric practice [2] - The course will feature prominent clinician-researchers, including BrainsWay's Chief Medical Officer Dr. Richard Bermudes and Vice President of Medical Affairs Dr. Colleen Hanlon, discussing innovative therapeutic approaches [2][3]